Bosutinib is used in the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients. Bosutinib Monohydrate was developed by American Cyanamid Co.
The API has now reached off-patent status, after being launched in 2012.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Bosutinib Monohydrate and many others, contact info@pharmacheminvestor.com